Search

Your search keyword '"Díez‐Álvarez, Elvira"' showing total 28 results
Start Over Author "Díez‐Álvarez, Elvira"
28 results on '"Díez‐Álvarez, Elvira"'

2. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study

Author

Cortés-Hernández, Josefina, Marras Fernández-Cid, Carlos, Andreu Sánchez, Jose Luis, Calvo Alén, Jaime, García-Aparicio, Angel M., Díez Álvarez, Elvira, Hidalgo Bermejo, Francisco Javier, Coronell, Carlos, Perna, Alessandra, and Ordi Ros, Josep

Published
2023
Full Text
View/download PDF

6. Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).

Author

Torrente-Segarra, Vicenç, Salman-Monte, Tarek C., Rúa-Figueroa, Íñigo, del Campo, Víctor, López-Longo, Francisco Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Olivé-Marqués, Alejandro, Mouriño-Rodríguez, Coral, Horcada, Loreto, Bohórquez, Cristina, Montilla, Carlos, Salgado, Eva, Díez-Álvarez, Elvira, Blanco, Ricardo, Andreu, José Luis, Fernández-Berrizbeitia, Olaia, Expósito, Lorena, Gantes, Marian, Hernández-Cruz, Blanca, Pecondón-Español, Ángela, Lozano-Rivas, Nuria, Bonilla, Gema, Lois Iglesias, Ana, Rubio-Muñoz, Paula, Ovalles, Juan, Tomero, Eva, Boteanu, Alina, Narvaez, Javier, Freire, Mercedes, Vela, Paloma, Quevedo-Vila, Víctor, Juan Mas, Antonio, Muñoz-Fernández, Santiago, Raya, Enrique, Moreno, Mireia, Velloso-Feijoo, ML, Soler, Gregorio, Vázquez-Rodríguez, Tomás Ramón, and Pego-Reigosa, José M.

Published
2020
Full Text
View/download PDF

8. LSO-089 Effectiveness of belimumab in systemic lupus erythematosus patients of a multicenter Spanish cohort

Author

Altabás-González, Irene, primary, Pego-Reigosa, José María, additional, Mouriño-Rodriguez, Coral, additional, Jiménez-Otero, Norman, additional, Hernández-Martín, Andrea, additional, Roman-Urgelles, Judit, additional, Casafont-Sole, Ivette, additional, Roman-Ivorra, José Andrés, additional, Rubia-Navarro, Marta De la, additional, Galindo-Izquierdo, María, additional, Salman-Montes, Tarek, additional, Narváez, Javier, additional, Vidal-Montal, Paola, additional, García-Villanueva, María Jesús, additional, Garrote-Corral, Sandra, additional, Blázquez-Cañamero, María Ángeles, additional, Marras-Fernández, Carlos, additional, Piqueras-García, María, additional, Martínez-Barrio, Julia, additional, Sánchez-Lucas, Marina, additional, Cortés-Hernández, Josefina, additional, Penzo, Eleonora, additional, Calvo-Alen, Jaime, additional, De Dios Jiménez de Aberásturi, Juan Ramón, additional, Álvarez-Rodríguez, Belén, additional, Rocha, Margarida Vasques, additional, Tomero, Eva, additional, Menor-Almagro, Raúl, additional, Gandía-Martínez, Myriam, additional, Gómez-Puerta, José A, additional, Frade-Sosa, Beatriz, additional, Ramos-Giráldez, Consuelo, additional, Trapero-Pérez, Carmen, additional, Díez-Álvarez, Elvira, additional, Moriano, Clara, additional, Muñoz-Jiménez, Alejandro, additional, and Rúa-Figueroa, Íñigo, additional

Published
2023
Full Text
View/download PDF

9. LP-191 Baseline profile of systemic lupus erythematosus patients on treatment with belimumab of a Spanish multicenter cohort

Author

Altabás-González, Irene, primary, Pego-Reigosa, José María, additional, Mouriño-Rodriguez, Coral, additional, Jiménez-Otero, Norman, additional, Hernández-Martín, Andrea, additional, Font-Urgelles, Judit, additional, Casafont-Sole, Ivette, additional, Roman-Ivorra, José Andrés, additional, Rubia-Navarro, Marta De La, additional, Galindo-Izquierdo, María, additional, Salman-Montes, Tarek, additional, Narváez, Javier, additional, Vidal-Montal, Paola, additional, García-Villanueva, María Jesús, additional, Garrote-Corral, Sandra, additional, Blázquez-Cañamero, María Ángeles, additional, Marras-Fernández, Carlos, additional, Piqueras-García, María, additional, Martínez-Barrio, Julia, additional, Sánchez-Lucas, Marina, additional, Cortés-Hernández, Josefina, additional, Penzo, Eleonora, additional, Calvo-Alen, Jaime, additional, Jiménez De Aberásturi, Juan Ramón De Dios, additional, Álvarez-Rodríguez, Belén, additional, Vasques-Rocha, Margarida, additional, Tomero, Eva, additional, Menor-Almagro, Raúl, additional, Gandía-Martínez, Myriam, additional, Gómez-Puerta, José A, additional, Ramos-Giráldez, Consuelo, additional, Trapero-Pérez, Carmen, additional, Díez-Álvarez, Elvira, additional, Moriano, Clara, additional, Muñoz-Jiménez, Alejandro, additional, and Rúa-Figueroa, Íñigo, additional

Published
2023
Full Text
View/download PDF

10. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus

Author

Rúa-Figueroa, Íñigo, López-Longo, Javier, Galindo-Izquierdo, María, Calvo-Alén, Jaime, Del Campo, Víctor, Olivé-Marqués, Alejandro, Pérez-Vicente, Sabina, Fernández-Nebro, Antonio, Andrés, Mariano, Erausquin, Celia, Tomero, Eva, Horcada, Loreto, Uriarte, Esther, Freire, Mercedes, Montilla, Carlos, Sánchez-Atrio, Ana, Santos, Gregorio, Boteanu, Alina, Díez-Álvarez, Elvira, Narváez, Javier, Martínez-Taboada, Víctor, Silva-Fernández, Lucía, Ruiz-Lucea, Esther, Andreu, José Luis, Hernández-Beriain, José Ángel, Gantes, Marian, Hernández-Cruz, Blanca, Pérez-Venegas, José, Pecondón-Español, Ángela, Marras, Carlos, Ibáñez-Barceló, Mónica, Bonilla, Gema, Torrente, Vicente, Castellví, Iván, Alegre, Juan José, Calvet, Joan, Marenco, Jose Luis, Raya, Enrique, Vázquez, Tomás, Quevedo, Victor, Muñoz-Fernández, Santiago, Rodríguez-Gómez, Manuel, Ibáñez, Jesús, and Pego-Reigosa, José M.

Published
2017
Full Text
View/download PDF

14. Reduction of disease activity, corticosteroids use, and healthcare resource utilisation in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: OBSErve Spain multicentre study

Author

Cortés-Hernández, Josefina, primary, Marras Fernández-Cid, Carlos, additional, Andreu Sánchez, Jose Luis, additional, Calvo Alén, Jaime, additional, García-Aparicio, Angel M., additional, Díez Álvarez, Elvira, additional, Hidalgo Bermejo, Francisco Javier, additional, Coronell, Carlos, additional, Perna, Alessandra, additional, and Ordi Ros, Josep, additional

Published
2022
Full Text
View/download PDF

16. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. National multicenter study of 51 cases in clinical practice.

Author

Atienza-Mateo, Belén, primary, Martín-Varillas, José Luis, additional, Graña, Jenaro, additional, Espinosa, Gerard, additional, Moriano, Clara, additional, Pérez-Sandoval, Trinidad, additional, Martín-Martínez, Manuel, additional, Díez-Álvarez, Elvira, additional, García-Armario, María Dolores, additional, Martínez, Esperanza, additional, Castellví, Iván, additional, Sivera, Francisca, additional, Calvo-Alen, Jaime, additional, Morena, Isabel de la, additional, Ortiz-Sanjuán, Francisco, additional, Román-Ivorra, José Andrés, additional, Pérez-Gómez, Ana, additional, Heredia, Sergi, additional, Olivé, Alejandro, additional, Prior-Español, Águeda, additional, Díez, Carolina, additional, Alegre, Juan José, additional, Ybáñez, Amparo, additional, Martinez-Ferrer, Angels, additional, Narváez, Javier, additional, Figueras, Ignasi, additional, Turrión, Ana Isabel, additional, Romero-Yuste, Susana, additional, Trénor, Pilar, additional, Ojeda, Soledad, additional, Ros, Inmaculada, additional, Loricera, Javier, additional, Calvo-Río, Vanesa, additional, González-Vela, Carmen, additional, Castañeda, Santos, additional, Hernández, José L., additional, Gonzalez-Gay, Miguel A., additional, and Blanco, Ricardo, additional

Published
2020
Full Text
View/download PDF

17. Hormonal Dependence and Cancer in Systemic Lupus Erythematosus

Author

Cobo‐Ibáñez, Tatiana, primary, Urruticoechea‐Arana, Ana, additional, Rúa‐Figueroa, Iñigo, additional, Martín‐Martínez, María A., additional, Ovalles‐Bonilla, Juan Gabriel, additional, Galindo, María, additional, Calvo‐Alén, Jaime, additional, Olivé, Alejandro, additional, Fernández‐Nebro, Antonio, additional, Menor‐Almagro, Raúl, additional, Tomero, Eva, additional, Horcada, Loreto, additional, Uriarte‐Itzazelaia, Esther, additional, Martínez‐Taboada, Víctor M., additional, Andreu, José Luis, additional, Boteanu, Alina, additional, Narváez, Javier, additional, Bohorquez, Cristina, additional, Montilla, Carlos, additional, Santos, Gregorio, additional, Hernández‐Cruz, Blanca, additional, Vela, Paloma, additional, Salgado, Eva, additional, Freire, Mercedes, additional, Hernández‐Beriain, José Ángel, additional, Díez‐Álvarez, Elvira, additional, Expósito, Lorena, additional, Fernández‐Berrizbeitia, Olaia, additional, Velloso‐Feijoo, María Luisa, additional, Ibáñez‐Barceló, Mónica, additional, Lozano‐Rivas, Nuria, additional, Bonilla, Gema, additional, Moreno, Mireia, additional, Raya, Enrique, additional, Quevedo‐Vila, Víctor Eliseo, additional, Vázquez‐Rodríguez, Tomas Ramón, additional, Ibáñez‐Ruan, Jesús, additional, Muñoz‐Fernández, Santiago, additional, Sánchez‐Alonso, Fernando, additional, and Pego‐Reigosa, José María, additional

Published
2020
Full Text
View/download PDF

18. 72 Lupus impact tracker is responsive to changes in physician (T2T) and patient (SLAQ, EQ5D) relevant outcomes in a large spanish lupus registry cohort

Author

Figueroa, Iñigo Rua, primary, Devilliers, Herve, additional, Maria Pego Reigosa, Jose, additional, González, Irene Altabás, additional, Narváez-García, Javier, additional, López-Longo, Francisco Javier, additional, Ovalles-Bonilla, Juan, additional, Alen, Jaime Calvo, additional, Izquierdo, Maria Galindo, additional, Nebro, Antonio Fernandez, additional, Ibáñez-Barcelo, Mónica, additional, Morales, Carlos Montilla, additional, García-Villanueva, Mª Jesús, additional, Vela-Casasempere, Paloma, additional, Ruiz-Lucea, María E, additional, Toyos-Sáenz-de-Miera, Francisco J, additional, A Hernández-Beriaín, José, additional, Díez-Álvarez, Elvira, additional, Block, Joel, additional, and Jolly, Meenakshi, additional

Published
2019
Full Text
View/download PDF

20. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries-Based Study

Author

Rúa-Figueroa, Iñigo, Fernández Castro, Mónica, Andreu, José L, Sanchez-Piedra, Carlos, Martínez-Taboada, Víctor, Olivé, Alejandro, López-Longo, Javier, Rosas, José, Galindo, María, Calvo-Alén, Jaime, Fernández-Nebro, Antonio, Alonso, Fernando, Rodríguez-Lozano, Beatriz, Alberto García Vadillo, Jesús, Menor, Raúl, Narváez, Francisco Javier, Erausquin, Celia, García-Aparicio, Ángel, Tomero, Eva, Manrique-Arija, Sara, Horcada, Loreto, Uriarte, Esther, Gil, Susana, Blanco, Ricardo, López-González, Ruth, Boteanu, Alina, Freire, Mercedes, Galisteo, Carlos, Rodríguez-Gómez, Manuel, Díez-Álvarez, Elvira, Pego-Reigosa, José M, and Sjogrenser and Relesser Researchers and EAS-SER Group

Subjects
Adult, Male, Comorbidity, Middle Aged, Cohort Studies, Cross-Sectional Studies, Sjogren's Syndrome, Cardiovascular Diseases, Prevalence, Humans, Lupus Erythematosus, Systemic, Female, Registries, Aged
Abstract

To compare the prevalence of the main comorbidities in 2 large cohorts of patients with primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), with a focus on cardiovascular (CV) diseases. This was a cross-sectional multicenter study where the prevalence of more relevant comorbidities in 2 cohorts was compared. Patients under followup from SJOGRENSER (Spanish Rheumatology Society Registry of Primary SS) and RELESSER (Spanish Rheumatology Society Registry of SLE), and who fulfilled the 2002 American-European Consensus Group and 1997 American College of Rheumatology classification criteria, respectively, were included. A binomial logistic regression analysis was carried out to explore potential differences, making general adjustments for age, sex, and disease duration and specific adjustments for each variable, including CV risk factors and treatments, when appropriate. A total of 437 primary SS patients (95% female) and 2,926 SLE patients (89% female) were included. The mean age was 58.6 years (interquartile range [IQR] 50.0-69.9 years) for primary SS patients and 45.1 years (IQR 36.4-56.3 years) for SLE patients (P Primary SS patients have a consistently less serious CV comorbidity burden and a lower prevalence of severe infection than those with SLE. In contrast, their risk of lymphoma is greater.

Published
2016
Full Text
View/download PDF

21. Characterization of Patients With Lupus Nephritis Included in a Large Cohort From the Spanish Society of Rheumatology Registry of Patients With Systemic Lupus Erythematosus (RELESSER)

Author

Galindo-Izquierdo, María, primary, Rodriguez-Almaraz, Esther, additional, Pego-Reigosa, José M., additional, López-Longo, Francisco J., additional, Calvo-Alén, Jaime, additional, Olivé, Alejandro, additional, Fernández-Nebro, Antonio, additional, Martinez-Taboada, Víctor, additional, Vela-Casasempere, Paloma, additional, Freire, Mercedes, additional, Narváez, Francisco J., additional, Rosas, José, additional, Ibáñez-Barceló, Mónica, additional, Uriarte, Esther, additional, Tomero, Eva, additional, Zea, Antonio, additional, Horcada, Loreto, additional, Torrente, Vicenç, additional, Castellvi, Iván, additional, Calvet, Joan, additional, Menor-Almagro, Raúl, additional, Zamorano, María A. Aguirre, additional, Raya, Enrique, additional, Díez-Álvarez, Elvira, additional, Vázquez-Rodríguez, Tomás, additional, García de la Peña, Paloma, additional, Movasat, Atusa, additional, Andreu, José L., additional, Richi, Patricia, additional, Marras, Carlos, additional, Montilla-Morales, Carlos, additional, Hernández-Cruz, Blanca, additional, Marenco de la Fuente, José L., additional, Gantes, María, additional, Úcar, Eduardo, additional, Alegre-Sancho, Juan J., additional, Manero, Javier, additional, Ibáñez-Ruán, Jesús, additional, Rodríguez-Gómez, Manuel, additional, Quevedo, Víctor, additional, Hernández-Beriaín, José, additional, Silva-Fernández, Lucía, additional, Alonso, Fernando, additional, Pérez, Sabina, additional, and Rúa-Figueroa, Iñigo, additional

Published
2016
Full Text
View/download PDF

22. Comprehensive Description of Clinical Characteristics of a Large Systemic Lupus Erythematosus Cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) With Emphasis on Complete Versus Incomplete Lupus Differences

Author

Rúa-Figueroa, Íñigo, primary, Richi, Patricia, additional, López-Longo, Francisco Javier, additional, Galindo, María, additional, Calvo-Alén, Jaime, additional, Olivé-Marqués, Alejandro, additional, Loza-Santamaría, Estíbaliz, additional, Vicente, Sabina Pérez, additional, Erausquin, Celia, additional, Tomero, Eva, additional, Horcada, Loreto, additional, Uriarte, Esther, additional, Sánchez-Atrio, Ana, additional, Rosas, José, additional, Montilla, Carlos, additional, Fernández-Nebro, Antonio, additional, Rodríguez-Gómez, Manuel, additional, Vela, Paloma, additional, Blanco, Ricardo, additional, Freire, Mercedes, additional, Silva, Lucía, additional, Díez-Álvarez, Elvira, additional, Ibáñez-Barceló, Mónica, additional, Zea, Antonio, additional, Narváez, Javier, additional, Martínez-Taboada, Víctor, additional, Marenco, José Luis, additional, de Castro, Mónica Fernández, additional, Fernández-Berrizbeitia, Olaia, additional, Hernández-Beriain, José Ángel, additional, Gantes, Marian, additional, Hernández-Cruz, Blanca, additional, Pérez-Venegas, José J., additional, Pecondón, Ángela, additional, Marras, Carlos, additional, Carreira, Patricia, additional, Bonilla, Gema, additional, Torrente, Vicente, additional, Castellví, Iván, additional, Alegre, Juan, additional, Moreno, Mireia, additional, Raya, Enrique, additional, de la Peña, Paloma García, additional, Vázquez, Tomás, additional, Aguirre, Ángeles, additional, Quevedo, Víctor, additional, and Pego-Reigosa, José M., additional

Published
2015
Full Text
View/download PDF

23. Comorbidities in Patients With Primary Sjögren's Syndrome and Systemic Lupus Erythematosus: A Comparative Registries‐Based Study

Author

Rúa‐Figueroa, Iñigo, Fernández Castro, Mónica, Andreu, José L., Sanchez‐Piedra, Carlos, Martínez‐Taboada, Víctor, Olivé, Alejandro, López‐Longo, Javier, Rosas, José, Galindo, María, Calvo‐Alén, Jaime, Fernández‐Nebro, Antonio, Alonso, Fernando, Rodríguez‐Lozano, Beatriz, Alberto García Vadillo, Jesús, Menor, Raúl, Narváez, Francisco Javier, Erausquin, Celia, García‐Aparicio, Ángel, Tomero, Eva, Manrique‐Arija, Sara, Horcada, Loreto, Uriarte, Esther, Gil, Susana, Blanco, Ricardo, López‐González, Ruth, Boteanu, Alina, Freire, Mercedes, Galisteo, Carlos, Rodríguez‐Gómez, Manuel, Díez‐Álvarez, Elvira, and Pego‐Reigosa, José M.

Abstract

To compare the prevalence of the main comorbidities in 2 large cohorts of patients with primary Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE), with a focus on cardiovascular (CV) diseases. This was a cross‐sectional multicenter study where the prevalence of more relevant comorbidities in 2 cohorts was compared. Patients under followup from SJOGRENSER (Spanish Rheumatology Society Registry of Primary SS) and RELESSER (Spanish Rheumatology Society Registry of SLE), and who fulfilled the 2002 American–European Consensus Group and 1997 American College of Rheumatology classification criteria, respectively, were included. A binomial logistic regression analysis was carried out to explore potential differences, making general adjustments for age, sex, and disease duration and specific adjustments for each variable, including CV risk factors and treatments, when appropriate. A total of 437 primary SS patients (95% female) and 2,926 SLE patients (89% female) were included. The mean age was 58.6 years (interquartile range [IQR] 50.0–69.9 years) for primary SS patients and 45.1 years (IQR 36.4–56.3 years) for SLE patients (P< 0.001), and disease duration was 10.4 years (IQR 6.0–16.7 years) and 13.0 years (IQR 7.45–19.76 years), respectively (P< 0.001). Smoking, dyslipidemia, and arterial hypertension were associated less frequently with primary SS (odds ratio [OR] 0.36 [95% confidence interval (95% CI) 0.28–0.48], 0.74 [95% CI 0.58–0.94], and 0.50 [95% CI 0.38–0.66], respectively) as were life‐threatening CV events (i.e., stroke or myocardial infarction; OR 0.57 [95% CI 0.35–0.92]). Conversely, lymphoma was associated more frequently with primary SS (OR 4.41 [95% CI 1.35–14.43]). The prevalence of severe infection was lower in primary SS than in SLE (10.1% versus 16.9%; OR 0.54 [95% CI 0.39–0.76]; P< 0.001). Primary SS patients have a consistently less serious CV comorbidity burden and a lower prevalence of severe infection than those with SLE. In contrast, their risk of lymphoma is greater.

Published
2017
Full Text
View/download PDF

25. Factors Associated With Adverse Outcomes in Uveitis Related to Spondyloarthritis: Development of an Outcome Score (SpA-U).

Author

Sieiro Santos C, Sendino-Tenorio I, Álvarez Castro C, Moriano Morales C, Cordero Coma M, and Díez Álvarez E

Subjects
Humans, Female, Inflammation, HLA-B27 Antigen, Spondylarthritis complications, Spondylarthritis diagnosis, Spondylarthritis epidemiology, Uveitis diagnosis, Uveitis epidemiology, Uveitis etiology, Spondylitis, Ankylosing complications
Abstract

Background: Evaluating the efficacy and refractoriness to treatment and determining factors associated with adverse outcomes in uveitis associated with spondylarthritis (SpA) are complicated by the lack of validated outcome measures., Objectives: The aims of this study were to develop an outcome score SpA-U in patients with uveitis associated with SpA and to determine factors associated with adverse outcomes in patients with uveitis under systemic treatment., Methods: The outcome score SpA-U was defined by best-corrected visual acuity, anterior chamber inflammation, macular edema and inflammation of posterior chamber, global assessment, and refractoriness to treatment. Factors associated with adverse outcomes in uveitis were studied using linear regression. For categorical factors, marginal averages and their SEs are displayed together with linear regression coefficients with 95% confidence intervals. For continuous factors, averages and SDs are reported in addition to linear regression coefficients with 95% confidence interval. Two regression coefficients are reported for each variable: unadjusted and adjusted for age at diagnosis and sex., Results: One hundred ninety-seven uveitis outbreaks were included. Sixty-two uveitis outbreaks (31%) were classified as severe, 42 as moderate (21%), and 93 as mild (47%) based on the definition and construction of outcome score. The results of the linear regression model revealed that the uveitis activity was more severe in patients with smoking history ( β = 0.34), axial and peripheral involvement ( β = 0.43), Ankylosing Spondylitis Disease Activity Score >2.1 ( β = 0.45), positive HLA-B27 ( β = 0.29), female sex ( β = 0.19), patients with C-reactive protein elevation ( β = 0.002), and bilateral ocular involvement ( β = 0.32). At the same time, shorter disease evolution ( β = -0.02) was associated with less severe uveitis activity., Conclusion: We have determined factors associated with adverse outcomes in patients with uveitis associated with SpA by developing an outcome score SpA-U that integrates ocular inflammatory activity, visual acuity, global assessment, and refractoriness to treatment., Competing Interests: The authors declare no conflict of interest., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2023
Full Text
View/download PDF

26. Juvenile- and adult-onset systemic lupus erythematosus: a comparative study in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER).

Author

Torrente-Segarra V, Salman Monte TC, Rúa-Figueroa I, Sánchez-Alonso F, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Ibañez-Ruán J, Horcada L, Sánchez-Atrio A, Montilla C, Melero González RB, Díez-Álvarez E, Martinez-Taboada V, Andreu JL, Fernández-Berrizbeitia O, Hernández-Beriain JÁ, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Marras C, Bonilla G, and Pego-Reigosa JM

Subjects
Adolescent, Adult, Child, Cohort Studies, Cross-Sectional Studies, Female, Humans, Lupus Erythematosus, Systemic immunology, Male, Middle Aged, Registries, Severity of Illness Index, Young Adult, Lupus Erythematosus, Systemic complications
Abstract

Objectives: We aimed to describe juvenile-onset systemic lupus erythematosus (jSLE) features and to establish its differences compared to adult-onset SLE (aSLE) from a large national database., Methods: Data from patients (≥4 ACR criteria) included in Spanish Society of Rheumatology Lupus Registry (RELESSER) were analysed. Sociodemographic, clinical, serological, activity, treatment, cumulative damage, comorbidities and severity data were collected. Patients with disease onset <18 years were described and compared to those with disease onset ≥18 years., Results: We reviewed 3,428 aSLE patients (89.6% women) and 484 jSLE patients (89.8% girls), 93% Caucasian (both groups). Mean age at diagnosis was 38.1±14 and 16.6±6.3 years (p<0.001) and mean age at the end of follow-up was 48.8±14.3 and 31.5±30 years (p<0.001), respectively. jSLE showed significantly more clinical (including lymphadenopathy, fever, malar rash, mucosal ulcers, pericarditis, pleuritis, Raynaud's phenomenon, lupus nephritis, recurrent nephritis, histologic nephritis changes, thrombocytopenia, haemolytic anaemia, thrombotic thrombocytopenic purpura, seizures, lupus headache and organic brain syndrome) and immunological (a-dsDNA and a-Sm antibodies, hypocomplementaemia) involvement than did aSLE, except for secondary Sjögren's syndrome, a-Ro antibodies, fibromyalgia and osteoporosis. jSLE also showed more SLE family history, longer diagnosis delay, higher SLEDAI and Katz scores, but lower Charlson scores than aSLE. Several specific domains were more frequently involved in SLICC/ACR DI in jSLE. jSLE patients more frequently underwent all SLE-related treatment and procedures, as well as dialysis and kidney transplantations., Conclusions: jSLE shares many clinical and serological features with aSLE. However, jSLE patients typically manifested more activity, severity, cumulative damage in certain areas, than their aSLE counterparts.

Published
2017

27. Fibromyalgia prevalence and related factors in a large registry of patients with systemic lupus erythematosus.

Author

Torrente-Segarra V, Salman-Monte TC, Rúa-Figueroa Í, Pérez-Vicente S, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, Ibañez-Ruán J, Horcada L, Sánchez-Atrio A, Montilla C, Rodríguez-Gómez M, Díez-Álvarez E, Martinez-Taboada V, Andreu JL, Fernández-Berrizbeitia O, Hernández-Beriain JA, Gantes M, Hernández-Cruz B, Pecondón-Español Á, Marras C, Bonilla G, and Pego-Reigosa JM

Subjects
Adult, Antibodies, Antinuclear analysis, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Patient Acuity, Prevalence, Registries statistics & numerical data, Retrospective Studies, Severity of Illness Index, Spain epidemiology, Depression diagnosis, Depression etiology, Depression physiopathology, Fibromyalgia diagnosis, Fibromyalgia epidemiology, Fibromyalgia etiology, Fibromyalgia psychology, Lupus Erythematosus, Systemic complications, Lupus Erythematosus, Systemic diagnosis, Lupus Erythematosus, Systemic epidemiology
Abstract

Objectives: The objective of this study is to determine the prevalence of fibromyalgia (FM) in systemic lupus erythematosus (SLE) patients and to study its relationship to depression and other SLE-related factors., Methods: A cross-sectional data analysis from the RELESSER-Transversal Spanish Registry, which includes SLE patients in a national multicentre retrospective charts review, was performed., Inclusion Criteria: patients who fulfilled ≥4 ACR 1997 SLE criteria. Main variables were disease duration, depression, sociodemographics, comorbidities, SLE activity symptoms, serological findings, therapies and different disease status indices. Statistical analyses included a descriptive, associative and logistic regression analyses. A literature review was performed., Results: 3,591 SLE patients were included, 90.1% women, 34.6 years of age at diagnosis (SD 14.6 years) and 93.1% Caucasians. FM prevalence was 6.2%. SLE patients with disease duration >5 years showed more FM than those with duration <5 years: 6.9% vs. 4.0%, respectively (p<0.05). SLE-FM patients showed higher prevalence of depression compared to non-FM-SLE patients: 53.1% vs. 14.6%, respectively (p<0.001). After adjusting by risk factors, the OR (CI) of suffering depression in FM-SLE patients was 6.779 (4.770-9.636), p<0.001. The OR of having secondary Sjögren's 2.447 (1.662-3.604), p<0.001, photosensitivity 2.184 (1.431-3.334), p<0.001, and oral ulcers 1.436 (1.005-2.051), p=0.047., Conclusions: Prevalence of FM in Caucasian SLE patients was high compared to the general population, and was significantly higher in those in later stages of disease. SLE patients with depression showed a strong risk of developing FM. Photosensitivity, oral ulcers and secondary Sjögren's were the only SLE-related factors associated with FM.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results